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Expression of melanoma differentiation associated gene-7 (mda-7) also known as interleukin 24 (IL-24) decreases
during melanoma cell differentiation and induces apoptosis in melanoma cells but not in melanocytes. Here we
identify a novel splice variant of the cancer growth suppressor gene mda-7/IL-24 (mda-7s) that is differentially
expressed in RNA preparations from normal human melanocytes, transformed melanocytes, nevi, subcutaneous
metastasis, lymph node metastasis, and melanoma cell lines. The 450 bp mda-7s mRNA encodes a protein of 63
residues with a molecular weight of 12 kDa. mda-7s lacks exons 3 and 5 of the full-length transcript and contains
only 14 amino acids of homology to MDA-7 located within the signal peptide region of the wild-type sequence.
Despite minimal homology, MDA-7S coprecipitates full length MDA-7 and reduces secretion of cotransfected MDA-7.
mda-7 and mda-7s are coexpressed in all RNA preparations other than subcutaneous and lymph node metastasis
where mda-7s expression is lacking. mda-7s expression is therefore linked to a non-metastatic phenotype.
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Melanoma currently affects one person in 70 with an in-
creasing lifetime risk and represents, in the advanced
stages of disease, a paradigm of oncological treatment re-
sistance (Soengas and Lowe, 2003). In the progression of
melanocytic transformation within normal nevi to radial and
the vertical growth phase melanoma eventually leading to
metastatic melanoma, cells of the melanocytic lineage lose
contact with keratinocytes and become resistant to
apoptosis induction by chemotherapeutic agents with a
corresponding reduction of median survival of patients
(Houghton and Polsky, 2002).
The melanoma differentiation-associated gene 7 (mda-
7), also known as interleukin 24 (IL-24), contains seven ex-
ons and is transcribed from a locus at 1q 34.2–41 which
contains several members of the IL-10 family of cytokines
(Huang et al, 2001). The full-length human mda-7 1718 nt
cDNA encodes a protein of 206 amino acids in the major
open-reading frame, with a predicted molecular weight of
23.8 kDa (Jiang et al, 1996), which, due to glycosylation,
migrates with an apparent molecular weight of 35 kDa
(Wang et al, 2002). Originally cloned as a gene upregulated
during terminal differentiation of melanoma cells induced by
recombinant human fibroblast interferon (IFN-b) and the
protein kinase C activator mezerein (Jiang et al, 1995),
MDA-7 expression levels progressively decrease during the
transformation of melanocytic cells to metastatic melanoma
(Ekmekcioglu et al, 2001). At supraphysiological levels,
MDA-7 selectively induces growth suppression and apop-
tosis in diverse human cancers including melanoma, breast,
colon, prostate, small cell lung, and pancreatic carcinoma
whereas no quantitatively significant effect is found in nor-
mal human cells such as melanocytes and endothelial cells
(Sarkar et al 2002). MDA-7 overexpression in a replication-
defective adenovirus (Ad.mda-7) in melanoma cells induces
activation of the growth arrest and DNA damage (GADD)
family genes (GADD153, GADD34, GADD45a, and GADD45g)
via p38 MAPK. This is associated with a reduction of BCL2
protein levels leading to induction of apoptosis in melanoma
cells but not in normal melanocytes (Sarkar et al, 2002). It
has also been reported that Ad.mda-7 transfection not only
confers growth suppression, but also arrests the cell cycle
at G2/M in melanoma cells (Ekmekcioglu et al, 2001).
Ad.mda-7 (INGN 241) has entered clinical trials for solid
tumors (Fisher et al, 2003).
As an IL-10 family cytokine, MDA-7 is secreted by con-
canavalin A-activated peripheral blood mononuclear cells
(Wang et al, 2002) and demonstrates immunostimulatory
activity (Caudell et al, 2002). Secreted MDA-7 binds two
functional heterodimeric receptors IL-20R1/IL-20R2 and IL-
22R1/IL-20R2 on target cells such as keratinocytes, which
leads to stat activation (Dumoutier et al, 2001; Wang et al,
2002).
Although mda-7 mRNA is found in normal human me-
lanocytes and metastatic melanoma cell lines at lower lev-
els, MDA-7 protein levels decrease in more advanced1Work carried out in Vienna, Austria.
Abbreviations: IL, interleukin; mda-7, melanoma differentiation-as-
sociated gene-7
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melanoma and metastatic disease (Su et al, 1998; Ekmek-
cioglu et al, 2001).
In recent years, the identification of tissue-specific dif-
ferential splicing of key gene products has greatly increased
the complexity of the transcriptome and led to further un-
derstanding of the control of functional protein expression
(Sorek and Amitai, 2001). During a search of GenBank-ex-
pressed sequenced tags, we identified examples of mda-7
splicing of exons 1–4 in prostate and colon tissue. To ex-
amine the role of differential mda-7 splicing in the me-
lanocytic lineage, we amplified mda-7 sequences by PCR
and identified a splice variant of mda-7 (mda-7s) in normal
human melanocytes, which lacks both exons 3 and 5. MDA-
7S has a molecular weight of 12 kDa, contains homologies
to wild-type MDA-7 derived only from exon 2, but het-
erodimerizes with wild-type MDA-7 and reduces secretion
of the wild-type protein. Subsequent screening of me-
lanoma RNA samples identified a complete lack of mda-7s
expression in subcutaneous metastatic tumor material, with
lymph node metastases demonstrating positive association
with a non-metastatic phenotype.
Results
Differential splicing of mda-7 and isolation of mda-7s
The full-length 1718 bp mda-7 mRNA (accession
NM_006850.1) transcript (Jiang et al, 1995) is spliced from
a 5532 bp locus at chromosome 1q 34.2–41 (Huang et al,
2001) on GenBank clone RP11-462N18 (accession
AC023534.3). Seven exons are spliced to form the mature
transcript in which the reading frame extends from exons 2
to 7. To investigate the possible role of differential splicing in
the control of mda-7 expression and function, we conduct-
ed BLAST searches of expressed sequence tag homologies
to the wild-type mda-7/IL-24 sequence. Two clones (ac-
cession numbers AW949784.1 and AW949792.1) isolated
from colon tumor material and a sequence isolated from
normal prostate gland tissue (AA370518.1) that showed di-
rect splicing of mda-7 exons 1–4 were identified. RT-PCR is
a highly sensitive method for detection of even single mol-
ecules of cDNA. To investigate the possibility of differential
splicing in the melanocytic lineage, cDNA preparations from
normal human melanocytes were PCR amplified by primer
sets spanning the coding region of mda-7. In addition to the
full-length mda-7 transcript, an additional smaller amplifi-
cant was also seen in all melanocytic preparations (Fig 3a,
lanes 1–4). Isolation, cloning, and sequencing of this tran-
script demonstrated the presence of a novel splice variant
(mda-7s) where exon 2 sequences, which contain the mda-7
start codon, are spliced directly to exon 4, and exon 4 se-
quences are spliced directly to exon 6 (Fig 1a and b). The
coding sequence of mda-7s and positions of inter-exonic
splicing are shown in Fig 1a. The predicted open reading
frame of mda-7s has 63 amino acid residues derived from
sequences located in exons 2, 4, 6, and 7 (Fig 1a). Protein
homology to wild-type MDA-7 is limited to 14 amino acids
derived from exon 2 (Fig 1a), since the exon 2 to exon 4
transition results in a frame shift, which is maintained after
the splicing of exon 4 to exon 6. These 14 amino acids
represent the initial residues of the 49 residue wild-type N-
terminal amino acid signal peptide sequence but lack the
signal peptidase cleavage sites between residues 49 and
50 of wild-type MDA-7 (Sauane et al, 2003). MDA-7S also
contains no predicted cleavage sites suggesting MDA-7S is
not secreted. Due to the low sequence homologies, MDA-
7S also lacks the IL-10 signature motif, N-glycosylation
sites, and the protein kinase c and casein kinase II phos-
phorylation motifs present in the wild-type sequence
(Sauane et al, 2003).
MDA-7S heterodimerizes with MDA-7 The molecular
mass of C-terminal HA-tagged MDA-7S as determined by
western blotting of transfected extracts is 12 kDa (data not
shown) approximating to the predicted MDA-7S molecular
mass (7.3 kDa) which increases to 9.2 kDa incorporating the
HA peptide. It is unlikely that this slight increase in observed
molecular weight is due to glycosylation since no N-linked
sequences are found and low probilities of O-linked
glycosylation are predicted with bioinformatics (data not
shown). The transfected MDA-7CTGFP fusion protein mi-
grates as predicted with a molecular weight of 62 kDa
equaling the sum of MDA-7 (35 kDa) and cycle 3 GFP (27
kDa) molecular masses (data not shown).
Since a common property of IL-10 family cytokines is
homodimerization (Fickenscher et al, 2002), we investigated
whether MDA-7S interacts in vitro with wild-type MDA-7.
HEK293 cells were cotransfected with the pMHmda-7s-HA,
pMH-HA, pmda-7CTGFP and pCTGFP plasmids. Following
immunoprecipitation with either anti-HA or anti-GFP anti-
bodies, associated proteins were detected by western
blotting with antibodies directed against GFP or HA, re-
spectively. The 12 kDa HA tagged MDA-7S associated with
the wild-type 62 kDa MDA-7CTGFP fusion protein when
precipitated with either the anti-HA (Fig 2a) or anti-GFP an-
tibodies (Fig 2b). Cotransfected pMHmda-7s-HA and
pCTGFP (Fig 2a) or pMH-HA and pmda-7CTGFP
(Fig 2b) showed no interaction.
To examine whether mda-7s interaction affects the mda-
7-mediated induction of apoptosis in melanoma cells, Me-
lJUSO cells were first transfected with pmda-7CTGFP and
monitored by flow cytometry. Twenty-four hours post
transfection, 1%–2% of cells were green fluorescent and
Figure1
Differential splicing ofmda-7 RNA. The mda-7 splice variant (mda-7s)
was amplified and cloned from normal human melanocytes. (a) mda-7s
is spliced ( # ) aberrantly between exons (E) 2 and 4, and exons 4 and 6
shown in the sequence traces (b) generating a reading frame between
exons 2 and 7. Homologies between the 206 residue wild-type MDA-7
and the 63 amino acid MDA-7S are restricted to 14 residues (under-
lined) derived from exon 2.
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all cells were permeable to the vital dye propidium iodide
after 48 h. Cotransfection with mda-7s did not influence the
kinetics of cell death induction.
Since IL-10 family cytokines are known to homodimerize
and MDA-7/MDA-7S homologies are confined to the leader
peptide sequence, we investigated the role of MDA-7S on
the secretion of MDA-7CTGFP. As previously reported
(Caudell et al, 2002), secreted MDA-7 accumulates in the
culture media of transfected HEK293 cells. In cells cot-
ransfected with pmda-7CTGFP and pMHmda-7s-HA, re-
duced secretion of wild-type MDA-7CTGFP is observed
(Fig 2c).
Association between mda-7s expression and metastatic
melanoma To evaluate the expression of mda-7s during
the transformation of melanocytes to metastatic melanoma,
mda-7 expression was analyzed by PCR. Normal human
melanocytes coexpress mda-7 and mda-7s (Fig 3a, lanes
1–4). RNA isolated from spontaneously transformed me-
lanocyte cultures (Fig 3a, lanes 5–7) which are cultured in
normal medium and correspond to the original melanocyte
culture RNA in lanes 2–4 (Fig 3a), respectively, also express
both mda-7 and mda-7s. To examine possible changes in
mda-7s expression during melanoma progression, samples
were compared from normal nevi, subcutaneous metastasis
(stage IV) and lymph node metastasis (stage IV). Similar to
melanocyte patterns, coexpression of mda-7 and mda-7s
was seen in normal nevi (Fig 3b, lanes 1–3) mirroring the
results obtained from spontaneously transformed me-
lanocyte cultures showing no association between mda-7s
expression and cellular transformation. Analysis of subcu-
taneous (Fig 3c, lanes 1–3) and lymph node metastatic
(Fig 3c, lanes 4–6) tumor material, however, demonstrated
no expression of mda7-s in independent patient samples
summarized in Table I, indicating an association between
loss of mda-7s expression and metastatic development.
With regard to mda-7 expression, we cannot exclude con-
tamination of melanoma samples with other cells such as
lymphocytes, which may express mda-7. Differential mda-
7s expression patterns were seen in melanoma cell lines. In
A375 and MelJUSO cells, coexpression of mda-7 and mda-
7s is seen (Fig 3d, lanes 1 and 3) whereas in the 607B cell
line, no expression of mda-7s was detected (Fig 3d, lane 2).
Expression levels of mda-7s were also assessed in a real
time PCR assay. Confirming the RT-PCR data, mda-7s is
expressed in melanocytes with normalized threshold cycle
values of 28.3  2.4 (mean three experiments) but is not
detected in metastatic melanoma samples within 40 cycles
of amplification (Fig 3e).
Discussion
Great interest in mda-7 as a clinically relevant, candi-
date tumor suppressor gene has been generated due to
its growth arrest and apoptosis-inducing properties in
Figure 2
Functional interaction between MDA-7 and MDA-7S. HEK293 cells
were transiently cotransfected with HA-tagged MDA-7S (pMHmda-
7sHA), wild-type mda-7 as a C-terminal GFP fusion protein (pmda-
7CTGFP), or the empty vectors pCTGFP and pMH-HA. Cell lysates
were precipitated either on anti-HA agarose (a) or with anti-GFP an-
tibodies on protein G (b) and supernatants were western blotted and
probed with monoclonal antibodies against GFP (a) or HA (b). MDA-7S-
HA coprecipitated the 62 kDa MDA-7CTGFP protein (a) and MDA-
7CTGFP, the 12 kDa MDA-7S-HA polypeptide (b), demonstrating func-
tional interaction between the proteins. (c) HEK293 cells were
transfected with pmda-7CTGFP and either pMHmda-7sHA or pMH-
HA and the levels of secreted MDA-7CTGFP were assessed in the
medium by western blotting. Coexpression of MDA-7CTGFP and MDA-
7S-HA significantly reduced secretion of MDA-7CTGFP.
Figure3
Expression of mda-7s during melanoma development. Expression
of mda-7, mda-7s, and b-tubulin mRNA expression was analyzed by
PCR in normal human melanocytes (a, lanes 1–4), spontaneously
transformed melanocytes (a, lanes 5–7), nevi (b, lanes 1–3), lymph node
metastasis (c, lanes 1–3), subcutaneous metastasis (c, lanes 4–6) and
the melanoma cell lines A375, 607B and MelJUSO (d, lanes 1–3). In
real-time PCR amplification of mda-7s (e), representative graphs show
expression levels in normal melanocytes (I) decreasing to undetectable
levels in metastatic melanoma samples within 40 cycles of amplifica-
tion (II). Normalized reporter signal represents fluorescence changes
adjusted to baseline before amplification and (Ct) the threshold cycle of
amplified products.
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melanoma cells which are not seen in normal human me-
lanocytes subjected to ectopic overexpression (Ekmekcio-
glu et al, 2001; Ellerhorst et al, 2002). Both mda-7 RNA and
MDA-7 expression are reduced during the progression of
melanoma, and significant differences in MDA-7 expression
between primary tumors and metastases have been report-
ed (Ellerhorst et al, 2002). Expression levels may therefore
be regarded as a diagnostic marker for disease progression
and adenoviral vectors encoding mda-7 (INGN 241) have
entered clinical trials (Fisher et al, 2003). During a BLAST
search of GenBank expressed sequence tag homologies to
the wild-type mda-7/IL-24 sequence, we identified two
clones from colon tumor material and a sequence isolated
from normal prostate gland tissue that showed direct splic-
ing of mda-7 exons 1–4. To investigate the possible role of
differential splicing in the control of MDA-7 expression and
function in the melanocytic lineage, we subsequently iso-
lated the mda-7s transcript, which is produced by direct
splicing of exons 2, 4, and 6. As common to the other se-
quences found in databanks, our data clearly show aberrant
splicing to exon 4 within the mda-7 gene. Mda-7s RNA also
contains the polyadenylation signal and the AU-rich mRNA
destabilization sequences in exon 7 that are essential for
protein-mediated post-transcriptional regulation of wild-
type mda-7 transcripts (Madireddi et al, 2000).
In general, alternative splicing often results in functional
protein expression (Rinfret and Anderson, 1993) and con-
siderably increases the transcriptome. Splice variant protein
expression may also lead to a reduction in functional
transcript expression leading to altered pathology (Hau
et al, 2002). This finding has been reported by a number
of groups and include the tumor suppressor gene men1
(Mutch et al, 1999), pten (Butler et al, 1999), nf-2 (Jacoby et
al, 1994), and the transcription factor pax-2 (Tavassoli et al,
1997). In recent years, the human-expressed sequence tag
(EST) database has been analyzed by a number of different
groups to investigate differential splicing (Sorek et al, 2001)
and it has been estimated that up to 59% of human genes
have at least two tissue-specific splice variants.
Since evidence of splice variants conferring dominant
negative effects has recently been reported (Korkalainen
et al, 2003), we investigated the effects of mda-7s on the
apoptosis-promoting properties of the wild-type protein. In
MelJuso melanoma cells, wild-type mda-7 rapidly induced
cell death, which was not inhibited by cotransfection with
an mda-7s expression plasmid demonstrating that het-
erodimeric MDA-7/MDA-7S expression has no effect on the
apoptosis-inducing properties of the wild-type protein. In
addition, MDA-7S expression levels were not significantly
decreased during spontaneously transformed melanocyte
cultures described previously (Selzer et al, 1998), indicating
that MDA-7S expression is not directly associated with
melanocyte transformation, nor by culture in melanocyte
growth medium which contains additional growth factors
and phorbol esters.
Predicted amino acid sequence homologies between
MDA-7S and MDA-7 are limited to the N-terminal 14 amino
acids derived from exon 2. MDA-7S, however, lacks the
signal peptidase cleavage sites present in wild type MDA-7
and no evidence of secretion is detected in transfected
HEK293 supernatants (data not shown). In contrast to other
IL-10 family cytokines, MDA-7 (IL-24) has an extended sig-
nal peptide sequence, the functional significance of which
has not been addressed. We show that MDA-7S has ho-
mology to MDA-7 only within this signal peptide sequence
and although homodimerization of wild-type MDA-7 has not
been reported, MDA-7S and MDA-7 proteins functionally
interact in vitro and secretion of transfected MDA-7 is in-
hibited. Future investigations of the MDA-7S residues re-
sponsible for interaction with wild-type MDA-7 should also
reveal whether MDA-7 homodimerizes similar to other IL-10
family cytokines. Studies to determine the precise subcel-
lular localization of MDA-7S are in progress and should lead
to a fuller understanding of the role of this heterodimerizat-
ion during the MDA-7 secretory process within melanocytic
cells.
During the rapid development of malignant melanoma,
transformed melanocytic lineage cells develop through
a vertical growth phase and become highly metastatic.
The exact expression patterns conferring a metastatic phe-
notype have not been elucidated. Although mda-7s expres-
sion is seen in melanocytes, transformed melanocytes and
normal nevi, a complete absence of expression is associ-
ated with both local (subcutaneous) and distant (lymph
node) metastasis. Since secreted MDA-7 binds IL-20R1/IL-
20R2 and IL-22R1/IL-20R2 on target cells lead to stat
activation (Wang et al, 2002), the decreases in mda-7 expres-
sion seen during the development of metastatic disease
may represent a previously unknown mechanism for MDA-7
secretion in the activation of accessory cells. Although the
precise role of MDA-7S in this process is unclear, this as-
sociation demonstrates that MDA-7S expression levels
could potentially play a role in advances of diagnosis when
determining the progression of a localized lesion and as-
sessing the disease stage of melanoma tumors.
In summary, this study has identified a novel mda-7
splice variant (mda-7s) in human melanocytes. The splice
variant was determined to have molecular weight of 12 kDa
and lacked exons 3 and 5 of mda-7 but functionally inter-
acted with and influenced the secretion of the wild-type
Table I. Summary of mda-7s expression status during meta-
static melanoma progression
Patient
sample Tissue type
Disease
stage Characterization
mda-7s
proﬁle
1 Nevi – Normal Positive
2 Nevi – Normal Positive
3 Nevi – Normal Positive
4 Subcutaneous III/IV Metastatic Negative
5 Subcutaneous III/IV Metastatic Negative
6 Subcutaneous III/IV Metastatic Negative
7 Lymph node III/IV Metastatic Negative
8 Lymph node IV Metastatic Negative
9 Lymph node IV Metastatic Negative
mda-7s expression is seen in nevi and primary stage I/II melanoma
tumors. In subcutaneous stage III/IV disease, lymph node metastatic
stage III/IV disease and terminal disease stages, no expression of mda-7s
is seen.
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protein in vitro. Subsequently, a screen of melanoma patient
samples was performed and lymph node metastatic and
subcutaneous metastatic tumors were identified as being
deficient of mda-7s message when assessed via both RT-
PCR and quantitative PCR.
Material and Methods
Cell culture MelJUSO, A375 (ATCC, Manassas, Virginia) and
607B melanoma cells, transformed melanocytes (Selzer et al,
1998), and the HEK293 cell line were maintained in Dulbecco’s
modified Eagle’s culture medium containing 4.5 g per liter glucose
(DMEM), supplemented with 10% fetal calf serum (Gibco, Paisley,
Scotland) and an antibiotic-antimycotic mix containing 100 U per
mL of penicillin, 100 mg per mL of streptomycin and 0.25 mg per mL
of amphotericin B (Gibco) in a fully humidified 5% CO2–95% am-
bient air atmosphere at 371C. Normal human melanocytes (Clone-
tics, Remagen, Germany) were cultured in serum-free melanocyte
growth medium (MGM-2) containing 10 mg per mL phorbol 12-
myristate-13-acetate, 0.5 mg per mL hydrocortisone, 5 mg per mL
insulin, 5 mg per mL human fibroblast growth factor, 50 mg per mL
gentamycin-sulfate, 50 mg per mL amphothericin-B supplemented
with bovine pituitary extract as recommended by the suppliers.
Subjects and RNA isolation Tumor material was collected at
the Department of Dermatology at the University of Vienna follow-
ing approval by the University of Vienna ethics committee. Tumor
samples were isolated after routine surgical removal and placed
immediately in RNAlater (Qiagen, Hilden, Germany). Melanocyte
and melanoma cell line pellets were resuspended and tissue sam-
ples homogenized in TRI Reagent (Sigma, St Louis, Mo.) and total
RNA was reverse transcribed with Oligo (dT)12–18 and SuperScript
II (Gibco) according to the manufacturer’s instructions. Institutional
Review Board approval was granted for this work.
PCR and vector construction Primer positions are based
on the mda-7/IL-24 sequence GenBank accession number
NM_006850.1. RT-PCR was independently performed with mda-7
forward (272 50-GAGATGAATTTTCAACAGAGGC-30 293) and re-
verse (895 50-CGAGCTTGTAGAATTTCTGCATCC-30 870) primers,
and the tubulin forward (1263 50-CATCCAGGAGCTCTTCAAGC-30
1282) and reverse (1442 50-CTCCTCACCGAAATCCTCCT-30 1461)
primers based on the b-tubulin RNA sequence (AF141349.1).
cDNA (1 mL) was amplified in a 100 mL reaction containing 200 mM
dNTPs, 1.5 mM MgCl2, 20 mM Tris-HCl (pH 8), 50 mM KCl, and 1 U
Platinum Taq polymerase (Invitrogen, San Diego, California) in a
GenAmp thermocycler 2400 (Applied Biosystems, Perkin-Elmer,
Foster City, California) by initial denaturation at 951C for 2 min, 35
cycles of amplification at 951C, denaturation for 30 s, annealing at
601C for 30 s, extension at 721C for 1 min and end extension at
721C for 7 min. PCR products were separated on 1% agarose gels
containing 0.5 mg per mL ethidium bromide at 1 V/cm in TBE buffer.
mda-7s fragments were gel purified with the QIAquick PCR Pu-
rification Kit (Qiagen) and sequenced on both strands with the
amplification primers on an ABI-Prism 3100 Genetic Analyzer (Ap-
plied Biosystems). The coding sequence of full length mda-7 was
amplified from melanocyte cDNA and gel purified as before and
cloned into the pcDNA3.1/CT-GFP-TOPO vector (Invitrogen) as a
C-terminal GFP fusion (mda-7-GFP) with the forward (272 50-
GAGATGAATTTTCAACAGAGGC-30 293) and reverse (50-CGAGC
TTGTAGAATTTCTGCATCC-30 868) primers, the reverse primer de-
leting the stop codon and inserting a 50 terminal G residue to
maintain the reading frame for GFP, according to the manufactur-
er’s instructions. The reading frame of mda-7s was amplified from
melanocyte cDNA using the forward (50-GGGGTACCCCGAGAT
GAATTTTCAACAG-30 289) and reverse (50-CGGAATTCCGCGTC
CAACTGTTTGAATG-30 801) primers incorporating KpnI and EcoRI
restriction sites, respectively. The PCR product was gel purified,
restriction digested and cloned as a C-terminal hemagglutinin
(HA)-tagged protein into the pMH vector (Roche, Basel, Switzer-
land) by standard procedures (pMHmda-7s-HA) and sequenced on
both strands with a ABI-Prism 3100 Genetic Analyzer (Applied
Biosystems).
Transfection and conditioned media HEK293 and MelJUSO
cells were transiently transfected with optimally diluted endotoxin-
free pmda-7-GFP and pMHmda-7s-HA plasmid preparations in
six-well plates in the presence of Fugene (Roche) at a DNA to lipid
ratio of 3:1. As assessed by flow cytometry in the presence of 5 mg
per mL propidium iodide, transfection efficiencies were 20%–30%
and 1%–2% for HEK293 and MelJUSO cells, respectively. Con-
ditioned media were harvested after 48 h.
Western blotting and immunoprecipitation Cells were harvest-
ed by trypsinization and washed first in cold complete medium and
subsequently in phosphate-buffered saline (PBS). Cells from cul-
tures in logarithmic growth, where cell viabilities were estimated at
greater than 99% by trypan blue exclusion, were lysed in hypotonic
lysis buffer (1% Triton X-100, 150 mM NaCl, 25 mM Tris, pH 7.4,
5 mg per mL leupeptin, aprotinin, and pepstatin, 1 mg per mL
benzamidine HCl, 1 mM sodium orthovanadate and 1 mM PMSF)
on ice at a density of approximately 106 cells per mL. Protein
concentrations were determined by a modified Bradford method
(Bio-Rad, Hercules, California). For immunoprecipitations, HEK293
cells were harvested in PBS and incubated in 1 mL of cell lysis
buffer (PBS containing 5 mM EDTA, 0.5% Triton X-100, 0.1 mM
PMSF, 5 mg per mL leupeptin, aprotinin, and pepstatin) for 30 min
on a rotary shaker at 41C. After centrifugation at 15,000  g for 30
min at 41C, supernatants were incubated with 100 mL anti-HA af-
finity matrix (clone 3F10; Roche) overnight or sequentially with
protein G-Agarose (Roche) for 1 h before addition of mouse mono-
clonal anti-GFP (clone ab1218; Abcam, Cambridge, UK). The ma-
trix was then washed three times in cell lysis buffer at 41C. Western
blotting was performed essentially as described (Lucas et al,
2001). Protein loading was routinely controlled by staining of gels
and membranes (Gelcode blue; Pierce, Rockford, Illinois). Briefly,
cell extracts, immunoprecipitates or conditioned medium were
mixed with loading buffer (62.5 mM Tris, pH 6.8%, 10% glycerol,
2% sodium dodecyl sulphate (SDS), 5% b-mercaptoethanol and
0.003% bromophenol blue) at a ratio of 1:1, boiled for 7 min at
951C and centrifuged at 15,000  g for 30 s. Proteins (15 mg per
lane) were separated by SDS polyacrylamide gel electrophoresis
(PAGE) at 100 V on 12% gels and transferred onto PVDF mem-
branes (Tropix, Foster City, California) at 100 V for 1.5 h. Mem-
branes were blocked for 1 h in 0.2% I-block (Tropix) in PBS and
then incubated with monoclonal mouse anti-GFP or rat anti-HA.
Membranes were then incubated with alkaline phosphatase con-
jugated anti mouse immunoglobulins (Tropix) or sequentially with
biotinylated monoclonal anti-rat IgG1 (clone RG11/39.4; Pharmin-
gen, San Diego, California) and alkaline phosphatase-conjugated
streptavidin (Pharmingen) in 0.2% I-block. Blots were then washed
twice in 0.2% I-block and developed using CSDP (Tropix).
Real-time PCR To detect mda-7s, a forward primer in exon 2 (281
50-TTTCAACAGAGGCTGCAAAGC-30 301) was combined with a
reverse primer in exon 4 (546 50-AGCCGGGCACTCGTGAT-30 530)
and a fluoresent (3030 50-TGTGGACTTTAGCCAGCAAGCTCAGGA-
30 525) probe spanning the exon 2/4 boundary. Primer positions are
based on the wild-type mda-7/IL-24 sequence (NM_006850.1).
PCR amplifications were performed on 2 mL of melanocytic or
melanoma cDNA samples with 5 pmol of FAM-labeled probe (VBC-
genomics, Vienna, Austria) and 5 pmol of primers in a 25 mL re-
action containing TaqMan Universal PCR master mix (Applied Bio-
systems). Real-time PCR was initiated at 501C for 2 min and 951C
for 10 min followed by 40 cycles of 951C for 15 s and 601C for 1 min
and threshold cycle values were analyzed with Sequence Detector
v1.7 software (Applied Biosystems) in a PRISM 7700 sequence
detector (Applied Biosystems) as described previously (Lucas et al,
2004).
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Sequence analysis Molecular mass predictions were calculated
with the Compute Mw tool (http://us.expasy.org/tools/pi_tool.
html), signal peptide recognition at SignalP V1.1 (http://www.cbs.
dtu.dk/services/SignalP) and homologies were determined at the
ncbi.nlm.nih.gov/blast interface.
Accession numbers The mda-7s sequence has the GenBank
accession number AY237723.
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